Healthy AdultsPhase 1NCT06619054
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of KP-001
A Phase 1 study testing KP-001 in people with Healthy Adults and Hepatic Impairment, run by Kaken Pharmaceutical at 1 site in United States.
Trial summary
This is a phase 1, open-label, non-randomized, parallel-group, single-dose study to assess the effect of hepatic impairment (assessed by the criteria of the Child-Pugh scale) on the pharmacokinetics (PK) and safety of KP-001 in adult male and non-childbearing potential female participants aged ≥20 years old. Read more about this study
- Who is it for?
- Ages 20 years and olderHealthy volunteers can take part
- Conditions the study is for
- Healthy Adults, Hepatic Impairment
- What is being tested?
- KP-001
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 siteUnited States
- Study dates
- 24 Oct 2024to 31 Jul 2025
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- ・All Participants (Cohorts 1 to 4)
- Participant is male or female and aged ≥20 years old at the time of signing the informed consent.
- Participant has body weight ≥40.0 kg and body mass index between 18.0 and 42.0 kg/m2 at screening.
- Female participant is a woman of non-childbearing potential who:
- Is postmenopausal with amenorrhea for at least 1 year prior to screening and with FSH of 40 IU/L or higher.
- OR
Show all 32Show fewer
- Has undergone one of the following:
- bilateral tubal ligation or bilateral salpingectomy
- hysterectomy
- bilateral oophorectomy
- Male participant who is sexually active with female partner(s) of childbearing potential must agree to use both a condom and spermicide from the day of the administration of KP-001 until 91 days after the administration of KP-001.
- Male participant must agree to not donate sperm from the day of the administration of KP-001 until 91 days after the administration of KP-001.
- Participant is capable of giving signed informed consent as described in Appendix 1, Section 10.1.3 which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
- ・Healthy Participants with Normal Hepatic Function (Cohort 1)
- Participant is of a gender matched to his/her matched participant enrolled in Cohort 3.
- Participant is of an age that is within ±10 years to his/her matched participant enrolled in Cohort 3.
- Participant has a body mass index within ±20% to his/her matched participant enrolled in Cohort 3.
- Participant is medically healthy with no clinically significant abnormal screening results (e.g., medical history, physical examination, laboratory profiles, vital signs, or ECGs), in the opinion of the Investigator or designee.
- If screening and/or admission results are abnormal, they may be repeated once at screening and/or once at admission to confirm the participant's eligibility.
- Participant whose AST and ALT at screening and admission meet the following: ALT and AST \< 2 ULN.
- Participant has negative results for hepatitis B, hepatitis C, and HIV antibody screens.
- Non-smoker and no use of other tobacco- or nicotine-containing products, as documented by history (no tobacco or nicotine use within 6 months prior to Screening) during the study.
- ・Participants with Hepatic Impairment (Cohorts 2 to 4)
- Participant whose Child-Pugh classification at screening and admission laboratory tests applies to any of the following:
- Cohort 2: Child-Pugh Grade A (score 5-6)
- Cohort 3: Child-Pugh Grade B (score 7-9)
- Cohort 4: Child-Pugh Grade C (score 10-15)
- Participant considered by the Investigator to be clinically stable with respect to underlying hepatic impairment, based on medical evaluation that includes medical and surgical history, as well as a complete physical examination including seated vital signs, 12-lead ECG, and laboratory test results.
- Participant whose laboratory abnormalities are judged by the investigator to be clinically acceptable.
- Participant has no clinical exacerbation of hepatic disease within 30 days prior to study intervention administration.
- Participant with negative hepatitis B surface antigen (HBsAg) at screening.
- Non-smoker and no use of other tobacco or nicotine-containing products during the study.
Who cannot join
- ・All Participants (Cohorts 1 to 4)
- Participant has a history or presence of hypersensitivity or idiosyncratic reaction to any components of the KP-001 formulation or any components of formulation used as study intervention during the study.
- Participant has a complication of drug allergies or history of drug allergies, or psychiatric disorder as determined by the Investigator or designee.
- Participant used any investigational drug in the last 30 days or 5 half-lives (if known), whichever is longer, prior to Day -1 of Treatment Period.
- Female participant has a positive pregnancy test or is lactating.
- Participant has positive urine drug or urine alcohol and positive cotinine test results at screening or Day -1 of Treatment Period.
Show all 32Show fewer
- Participant who cannot administer drugs orally.
- Participant is unable or unwilling to undergo multiple venipunctures.
- Participant underwent blood donation or transfusion within 56 days prior to Day -1 of Treatment Period.
- Participant has consumed alcohol- or caffeine-containing foods and beverages within 72 hours prior to Day -1 of Treatment Period and does not agree to refrain from consuming during the entire study, unless deemed acceptable by the Investigator.
- Participant has consumed grapefruit-containing foods and beverages within 7 days prior to Day -1 of Treatment Period and does not agree to refrain from consuming during the entire study.
- Participant has consumed St. John's wort-containing foods and beverages within 14 days prior to Day -1 of Treatment Period and does not agree to refrain from consuming during the entire study.
- Participated in strenuous exercise from 48 hours prior to Check-in (Day -1) or during the study through the final end of study assessment.
- Participant is legally, mentally or physically incapacitated or, in the opinion of the Investigator, has significant mental or emotional problems, including psychiatric illness (e.g., depression and/or anxiety) at the time of the Screening Visit, or that could reasonably be expected to develop during the conduct of the study.
- Participant had any laboratory abnormality that, in the judgment of the Investigator, would put the participant at unacceptable risk for participation in the study or may interfere with the assessments included in the study.
- Participant has abnormal findings on the screening ECG deemed clinically significant by the Investigator or qualified designee.
- Participant is an employee of the Sponsor or any CRO involved in the study, the Investigator, or an immediate family member (partner, offspring, parents, siblings, or sibling's offspring) of an employee involved in the study.
- Any other reason that would render the participant unsuitable for study enrollment at the discretion of the Investigator.
- A participant who has received proton pump inhibitors (PPIs), histamine type-2 (H2)-receptor antagonists, or antacids during the 5-day period immediately preceding and including the admission day (or for 5 half-lives of the medication whichever is longer), or plan to receive any of these medications during treatment period (ie, until Day 3 [Discharge]).
- ・Healthy Participants with Normal Hepatic Function (Cohort 1)
- Participant has a significant history or clinical manifestation of any metabolic, allergic, dermatologic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder as determined by the Investigator or designee.
- Participant has a history of any illness that, in the opinion of the Investigator or designee, might confound the results of the study or poses an additional risk to the participant by their participation in the study.
- Participant had any major illness within 30 days before the Screening Visit.
- Participant had any major surgical procedure within 30 days prior to Day -1 of Treatment Period or any planned surgery during study period.
- Participant has a history or presence of liver disease or cholecystectomy within one year prior to screening.
- Participant has a disorder or any condition that would interfere with the absorption, distribution, metabolism, or excretion of drugs.
- Participant used any prescription or non-prescription medications (including vitamins, recreational drugs, and dietary or herbal supplements) within 14 days or 5 half-lives (whichever is longer) prior to Day -1 of Treatment Period and until completion of the Followup Visit unless, in the opinion of the Investigator, may be treatment for an AE or will not interfere with the interpretation of safety.
- ・Participants with Hepatic Impairment (Cohorts 2 to 4)
- Participant with any concomitant disease or condition considered clinically significant that, in the opinion of the investigator, may interfere with the investigational product, pose an unacceptable risk to the participant, or significantly increase the risk to the integrity or utility of the trial data (including treatment of such conditions).
- Participant with acute or chronic conditions other than liver (including, but not limited to, poorly controlled diabetes and grade 3 or higher encephalopathy) that, in the opinion of the investigator, would limit the participant\'s ability to complete the study and/or participate in this study.
- Participant with acute exacerbation of liver dysfunction or unstable liver function as determined by the investigator by Day 1 from screening.
- Participant who is positive for HBsAg, hepatitis C or HIV at screening. Participants with hepatitis C will also be accepted if, in the investigator\'s judgement, they are clinically stable and not receiving active treatment.
Trial locations and contacts
1 site in 1 country.
United States1 site
Sites contracted by Parexel
San Antonio, Texas, 08103
About this study
Official title: An Open-label, Single-dose Study for the Evaluation of the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of KP-001
This is a phase 1, open-label, non-randomized, parallel-group, single-dose study to assess the effect of hepatic impairment (assessed by the criteria of the Child-Pugh scale) on the pharmacokinetics (PK) and safety of KP-001 in adult male and non-childbearing potential female participants aged ≥20 years old.
The purpose of this study is to evaluate the effect of hepatic impairment on the PK and safety of KP-001. The study will also assess the effect of hepatic impairment on other PK parameters after single dose administration of KP-001.
Read more
The study will comprise 3 parts, and the study period for each part will consist of the following:
- Screening period: Up to 28 days before the administration of study intervention
- Treatment Period: Participants will be residential at the Clinical Unit from the day before the administration of the single dose of KP-001 (Day -1) until Day 3 (Discharge)
- Follow-up Visit: 7 days after discharge from the Clinical Unit (ie, Day 10) Participants will be enrolled into 4 cohorts according to the hepatic function status as summarized below. The study includes a control group of healthy participants with normal hepatic function.
- Conditions
- Healthy Adults, Hepatic Impairment
- Being tested
- KP-001
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
KP-001Drug
Oral single dose 50mg.
| Study group | Role | What they receive |
|---|---|---|
| Cohort1 (Normal) | Experimental | Child-Pugh Score: N/A Receives: Drug: KP-001 |
| Cohort2 (Mild Impairment) | Experimental | Child-Pugh Score: A (5 to 6 points) Receives: Drug: KP-001 |
| Cohort3 (Moderate Impairment) | Experimental | Child-Pugh Score: B (7 to 9 points) Receives: Drug: KP-001 |
| Cohort4 (Severe Impairment) | Experimental | Child-Pugh Score: C (10 to 15 points) Receives: Drug: KP-001 |
What is being measured
The primary outcome is the main question the study is designed to answer.
PK parameters of KP-001 in plasma: Cmax
To evaluate the effect of hepatic impairment on the PK and safety of KP-001
Measured: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
PK parameters of KP-001 in plasma:AUC0-inf
To evaluate the effect of hepatic impairment on the PK and safety of KP-001
Measured: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
Secondary outcomes (6)
PK parameters of KP-001 in plasma: AUC0-last
To assess the effect of hepatic impairment on other PK parameters after single dose administration of KP-001
Measured: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
PK parameters of KP-001 in plasma: t1/2
To assess the effect of hepatic impairment on other PK parameters after single dose administration of KP-001
Measured: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
PK parameters of KP-001 in plasma: λz
To assess the effect of hepatic impairment on other PK parameters after single dose administration of KP-001
Measured: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
PK parameters of KP-001 in plasma: CL/F
To assess the effect of hepatic impairment on other PK parameters after single dose administration of KP-001
Measured: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
PK parameters of KP-001 in plasma: Vz/F
To assess the effect of hepatic impairment on other PK parameters after single dose administration of KP-001
Measured: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
PK parameters of KP-001 in plasma: Tmax
To assess the effect of hepatic impairment on other PK parameters after single dose administration of KP-001
Measured: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2024
- Study start24 Oct 2024
- Primary completion16 May 2025
- Study completion31 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy AdultsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 24 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kaken Pharmaceutical
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06619054
- Sponsor's protocol ID
- KP-001-105
- Status last verified
- Oct 2025
- First submitted
- 12 Sep 2024
- Last updated
- 31 Oct 2025
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-label, Single-dose Study for the Evaluation of the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of KP-001
- ClinicalTrials.gov ID
- NCT06619054
- Acronym / sponsor ID
- KP-001-105
- Conditions
- Healthy Adults, Hepatic Impairment
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 24 participants (actual)
- Lead sponsor
- Kaken PharmaceuticalIndustry (pharma, biotech, devices)
- Study start
- 24 Oct 2024 (actual)
- Primary completion
- 16 May 2025 (actual)
- Study completion
- 31 Jul 2025 (actual)
- First posted
- 1 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a phase 1, open-label, non-randomized, parallel-group, single-dose study to assess the effect of hepatic impairment (assessed by the criteria of the Child-Pugh scale) on the pharmacokinetics (PK) and safety of KP-001 in adult male and non-childbearing potential female participants aged ≥20 years old.
The purpose of this study is to evaluate the effect of hepatic impairment on the PK and safety of KP-001. The study will also assess the effect of hepatic impairment on other PK parameters after single dose administration of KP-001.
The study will comprise 3 parts, and the study period for each part will consist of the following:
- Screening period: Up to 28 days before the administration of study intervention
- Treatment Period: Participants will be residential at the Clinical Unit from the day before the administration of the single dose of KP-001 (Day -1) until Day 3 (Discharge)
- Follow-up Visit: 7 days after discharge from the Clinical Unit (ie, Day 10) Participants will be enrolled into 4 cohorts according to the hepatic function status as summarized below. The study includes a control group of healthy participants with normal hepatic function.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Cohort1 (Normal) | Experimental | Drug: KP-001Child-Pugh Score: N/A |
| Cohort2 (Mild Impairment) | Experimental | Drug: KP-001Child-Pugh Score: A (5 to 6 points) |
| Cohort3 (Moderate Impairment) | Experimental | Drug: KP-001Child-Pugh Score: B (7 to 9 points) |
| Cohort4 (Severe Impairment) | Experimental | Drug: KP-001Child-Pugh Score: C (10 to 15 points) |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (32 listed)
- ・All Participants (Cohorts 1 to 4)
- Participant is male or female and aged ≥20 years old at the time of signing the informed consent.
- Participant has body weight ≥40.0 kg and body mass index between 18.0 and 42.0 kg/m2 at screening.
- Female participant is a woman of non-childbearing potential who:
- OR
Key exclusion criteria (32 listed)
- ・All Participants (Cohorts 1 to 4)
- Participant has a history or presence of hypersensitivity or idiosyncratic reaction to any components of the KP-001 formulation or any components of formulation used as study intervention during the study.
- Participant has a complication of drug allergies or history of drug allergies, or psychiatric disorder as determined by the Investigator or designee.
- Participant used any investigational drug in the last 30 days or 5 half-lives (if known), whichever is longer, prior to Day -1 of Treatment Period.
- Female participant has a positive pregnancy test or is lactating.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| KP-001Oral single dose 50mg. | Drug | Cohort1 (Normal), Cohort2 (Mild Impairment), Cohort3 (Moderate Impairment), Cohort4 (Severe Impairment) |
Primary outcome
PK parameters of KP-001 in plasma: Cmax
Time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
To evaluate the effect of hepatic impairment on the PK and safety of KP-001
PK parameters of KP-001 in plasma:AUC0-inf
Time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
To evaluate the effect of hepatic impairment on the PK and safety of KP-001
6 secondary outcomes
PK parameters of KP-001 in plasma: AUC0-last
Time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
PK parameters of KP-001 in plasma: t1/2
Time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
PK parameters of KP-001 in plasma: λz
Time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
PK parameters of KP-001 in plasma: CL/F
Time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
PK parameters of KP-001 in plasma: Vz/F
Time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
PK parameters of KP-001 in plasma: Tmax
Time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Oct 2025.
Related trials for Healthy Adults
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingPhase 1/2
Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) Vaccine
Human Papillomavirus Infection
Not yet recruiting
REM Enhancement Sleep Technology for Well-being, Emotion, and Life Lift
Healthy Adult Participants
Not yet recruitingPhase 1
Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates
Influenza
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing KP-001 in people with Healthy Adults and Hepatic Impairment, run by Kaken Pharmaceutical at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 32 inclusion and 32 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
PK parameters of KP-001 in plasma: Cmax (time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Oct 2025.